Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257486 | 0.90 | LMNA (0.39) | DNM1TSHRFDPSLMNA | |
| SCHEMBL9419491 | 0.90 | — | — | |
| SCHEMBL384819 | 0.86 | DNM1 (0.45) | DNM1MMP13ALDH1A1TDP1TSHR | |
| SCHEMBL6255309 | 0.85 | LMNA (0.39) | DNM1TSHRFDPSLMNA | |
| SCHEMBL10947406 | 0.83 | DNM1 (0.43) | DNM1MMP13ALDH1A1TDP1TSHR | |
| Hydrochloric Acid SCHEMBL965472 | 0.83 | DNM1 (0.43) | DNM1MMP13ALDH1A1TDP1TSHR | |
| SCHEMBL10941450 | 0.83 | DNM1 (0.43) | DNM1MMP13ALDH1A1TDP1TSHR | |
| Bromide SCHEMBL3385366 | 0.83 | DNM1 (0.43) | DNM1MMP13ALDH1A1TDP1TSHR | |
| Iodide SCHEMBL6383667 | 0.83 | DNM1 (0.43) | DNM1MMP13ALDH1A1TDP1TSHR | |
| Water SCHEMBL7551987 | 0.83 | DNM1 (0.43) | DNM1MMP13ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1496943-A4 | OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS | ISIS PHARMACEUTICALS INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20060003952-A1 | Oligomeric compounds having modified phosphate groups | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6942966-B1 | libraries formed by permutations; combinatorial chemistry; drug screening | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-6933288-B2 | Pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2005-08-23 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050106598-A1 | Novel peptide-conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6878805-B2 | Peptide-conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| WO-1995023160-A1 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995018623-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106598-A1 | Novel peptide-conjugated oligomeric compounds | IAPP, NGLY1, TAP1 | DNM1 194/4885MMP13 3633/4885ALDH1A1 4829/4885 |
| US-20060003952-A1 | Oligomeric compounds having modified phosphate groups | POLRMT, SNRPE, POLM | DNM1 1500/4885MMP13 4428/4885ALDH1A1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.